Not yet taking people in ArgentinaPhase 3

Eloralintide Study for Weight, Diabetes and Heart Risk in Adults

Tests eloralintide against placebo in adults with obesity, diabetes and heart risk.

Plain-language title generated from the registry record
Registry title: A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk

Key facts

Where: Buenos Aires, CABA, Córdoba, Granadero Baigorria, Lanus, Mar del Plata, Ramos Mejía, Rosario, San Fernando, San Nicolás, and Santa Fe, ArgentinaSee the 23 sites
Phase: Phase 3

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 45 to 64 with type 2 diabetes, overweight or obesity, and a higher risk of heart and blood vessel problems.

Age: 45 to 64 years
Sex: All sexes can join.
Disease stage: Type 2 diabetes with HbA1c between ≥ 6.5% (48 mmol/mol) and ≤ 9.5% (80 mmol/mol), BMI ≥ 25.0 kg/m2, and an increased risk of cardiovascular events.
Earlier treatment: On stable treatment with an unchanged dose of at least 1 and no more than 4 antihyperglycemic therapies for at least 90 days before screening. At least one self-reported unsuccessful dietary effort to lose weight.
Biomarker or test result: HbA1c between ≥ 6.5% (48 mmol/mol) and ≤ 9.5% (80 mmol/mol) at screening.

Main reasons for not taking part

Type 1 diabetes
Prior or planned surgery, endoscopic procedure or device-based therapy for obesity (some exceptions apply)
New York Heart Association Functional Classification IV congestive heart failure
Within 60 days before screening: heart attack, stroke, hospitalization for heart failure, or artery revascularization
Sulfonylurea combined with insulin within 90 days before screening

Read by machine on 9 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

Are you between 45 and 64 years old?

Source: NCT07900633, who can take part

Where in Argentina

CARDIAMET Investigaciones MédicasBuenos Aires, ArgentinaContact: Angela Romero Zarante (principal investigator)No longer taking part
Centro de Investigaciones Metabólicas (CINME)Buenos Aires, ArgentinaContact: Federico Perez Manghi (principal investigator)No longer taking part
Centro Medico Dra. Laura Maffei- Investigacion Clinica AplicadaBuenos Aires, ArgentinaContact: Mariana Scandizzo (principal investigator)No longer taking part
Centro Médico ViamonteBuenos Aires, ArgentinaContact: Diego Aizenberg (principal investigator)No longer taking part
CIPRECBuenos Aires, ArgentinaContact: Cesar Zaidman (principal investigator)No longer taking part
Fundacion RespirarBuenos Aires, ArgentinaContact: Maria Nemesio (principal investigator)No longer taking part
Investigaciones Medicas Imoba SrlBuenos Aires, ArgentinaContact: Silvia Orio (principal investigator)No longer taking part
Mautalen Salud e InvestigaciónBuenos Aires, ArgentinaContact: Jose Fretes (principal investigator)No longer taking part
CEDICCABA, ArgentinaContact: Cecilia Igarzabal (principal investigator)No longer taking part
Centro Diabetológico Dr. WaitmanCórdoba, ArgentinaContact: Silvana Ernestina Solis (principal investigator)No longer taking part
Instituto de Investigaciones Clínicas CórdobaCórdoba, ArgentinaContact: Ines Bartolacci (principal investigator)No longer taking part
Centro de Investigaciones Clínicas BaigorriaGranadero Baigorria, ArgentinaContact: Juan Dominguez (principal investigator)No longer taking part
CIMeLLanus, ArgentinaContact: Mariano Chahin (principal investigator)No longer taking part
Centro de Investigaciones Medicas Mar Del PlataMar del Plata, ArgentinaContact: Andres Alvarisqueta (principal investigator)No longer taking part
Instituto de Investigaciones Clinicas Mar del PlataMar del Plata, ArgentinaContact: Virginia Sernia (principal investigator)No longer taking part
DIM Clínica PrivadaRamos Mejía, ArgentinaContact: Oscar Montaña (principal investigator)No longer taking part
INECO Neurociencias OroñoRosario, ArgentinaContact: María Cappiello (principal investigator)No longer taking part
Instituto de Investigaciones Clinicas RosarioRosario, ArgentinaContact: Carolina Chacón (principal investigator)No longer taking part
Instituto Médico Catamarca IMECRosario, ArgentinaContact: Natacha Maldonado (principal investigator)No longer taking part
Instituto Médico Fundación Grupo Colaborativo Rosario Investigación y Prevención MedicaRosario, ArgentinaContact: Horacio Sessa (principal investigator)No longer taking part
Centro Médico RespireSan Fernando, ArgentinaContact: Pablo Sorensen (principal investigator)No longer taking part
Go Centro Medico San NicolásSan Nicolás, ArgentinaContact: Paulina Lanchiotti (principal investigator)No longer taking part
Centro de Investigaciones Clinicas del LitoralSanta Fe, ArgentinaContact: Miguel Hominal (principal investigator)No longer taking part

Questions to ask the study team

How often do I need to come in, and for how long each time?
Are travel costs paid?
Can I keep my own doctor?
What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it: Eli Lilly and Company
Trial code: NCT07900633 EU 2026-525919-14-00
Record updated: 3 November 2026
Original description: The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with a placebo in participants with obesity or overweight, type 2 diabetes, and increased cardiovascular risk.Read full original descriptionShow less
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once-Weekly Eloralintide in Adult Participants With Obesity or Overweight, Type 2 Diabetes, and Increased CV Risk
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with a placebo in participants with obesity or overweight, type 2 diabetes, and increased cardiovascular risk.
Inclusion: Have type 2 diabetes; Have a HbA1c value between ≥ 6.5% and ≤ 9.5% at screening; Are on stable treatment with an unchanged dose of at least 1 and no more than 4 antihyperglycemic therapies for at least 90 days before screening; Have an increased risk of cardiovascular events; Have a BMI ≥ 25.0 kg/m2 at screening; Have a stable body weight (<5% body weight change) for 90 days prior to screening; Have a history of at least one self-reported unsuccessful dietary effort to reduce body weight.
Exclusion: Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening); Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening); Have had within 60 days prior to screening:; acute myocardial infarction; stroke; hospitalization for congestive heart failure, or; coronary, peripheral, or carotid artery revascularization procedure; Have received treatment combining sulfonylurea and insulin within 90 days prior to screening; Have type 1 diabetes; Have a history or diagnosis of New York Heart Association Functional Classification IV congestive heart failure.
ClinicalTrials.gov NCT07900633 · EU CTIS 2026-525919-14-00